Skip to content
DataLookout
Menu

NCT02827877

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 18 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Jul 15, 2016 to Feb 14, 2018
    • Eligibility criteria expanded, about 12 words
    • Study completion pushed from Sep 25, 2026 to Aug 26, 2027
  2. Minor Study completion date: Oct 16, 2025 to Sep 25, 2026v20
  3. Minor Study completion date: Jun 1, 2025 to Oct 16, 2025v19
  4. Minor Study completion date: Dec 30, 2024 to Jun 1, 2025v18
  5. Minor Study completion date: Dec 30, 2023 to Dec 30, 2024v17
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Study completion date: Jun 30, 2023 to Dec 30, 2023v16
  2. Notable Results first posted: Mar 9, 2023
    • Primary endpoints: 3 to 1
    • Study completion date: Dec 31, 2021 to Jun 30, 2023
    • Study title shortened, about 8 words
    v15
  3. Minor Primary completion date: Apr 13, 2020 to Jul 2, 2020v14
  4. Minor Trial status: Recruiting to Active, Not Recruitingv13 Show 4 more changesShow less
    • Enrollment target: estimated 20 to confirmed 18
    • Primary completion date changed from estimate of Feb 2021 to Apr 13, 2020
    • Study completion date: Feb 2021 to Dec 31, 2021
    • Site details revised
  5. Notable Primary and study completion dates: Feb 2020 to Feb 2021v12
  6. Notable Phase: Not applicable to Phase 2
    • Eligibility criteria revised
    • Study description expanded, about 1 word
    v11
  7. Notable Primary and study completion dates: Feb 2019 to Feb 2020v10
  8. Minor Primary and study completion dates: Dec 2018 to Feb 2019v8
  9. Minor Study description revisedv7
  10. Notable Eligibility criteria shortened, about 5 wordsv5
  11. Minor Primary and study completion dates: Oct 2018 to Dec 2018
    • Start date: Jul 2016 to Jul 15, 2016
    v4
  12. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Eligibility criteria expanded, about 4 words
    • Start date: Oct 2016 to Jul 2016
    • Interventions: Chemotherapy (Drug), Copper Cu 64-DOTA-Trastuzumab (Radiation), Laboratory Biomarker Analysis (Other), Pertuzumab (Biological), Positron… to Copper Cu 64-DOTA-Trastuzumab (Radiation), Laboratory Biomarker Analysis (Other), Pertuzumab (Biological), Positron Emission Tomography…
    • Study description shortened, about 44 words
    • Site details revised
    • Study title expanded, about 1 word
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Response to Neoadjuvant Chemotherapy Determined at Surgery (Lumpectomy or Mastectomy).
Timeframe: Up to 1 year

Arms and interventions

Treatment (trastuzumab, copper Cu 64-DOTA-trastuzumab PET)Experimental

Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 cycles of trastuzumab and pertuzumab.

Radiation: Copper Cu 64-DOTA-Trastuzumab

Other: Laboratory Biomarker Analysis

Biologicals: Pertuzumab, Trastuzumab

Procedures: Positron Emission Tomography, Therapeutic Conventional Surgery

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States